Amgen (AMGN): biotech and rate exposure
How global shocks reach AMGN
Amgen is filed under Biotechnology, and 5 of the 6 shock types GLOBLVIEW tracks reach it through that sector (oil shock, conflict risk, chip/export, trade/tariff, rates/fed). Stories centered on the United States also register as geographic exposure, because Amgen is registered in the United States.
| Shock | Channel | Tendency for AMGN | Why |
|---|---|---|---|
| OIL SHOCK | Input costs | ▼ tends to be pressured | Direct energy use is a small cost for biotechnology. Higher oil prices reach it through weaker demand and higher rates, not through input costs. |
| CONFLICT RISK | Risk appetite | ▼ tends to be pressured | Rising conflict risk tends to weigh on biotechnology, since investors trim exposure to anything read as discretionary or growth-dependent. |
| CHIP/EXPORT | Rules and access | ▼ tends to be pressured | Tighter export and chip rules tend to hurt biotechnology, cutting off supply, customers, or both. |
| TRADE/TARIFF | Revenue exposure | ▼ tends to be pressured | New tariffs tend to raise costs or shrink markets for biotechnology, since it depends on cross-border supply chains or sales. |
| RATES/FED | Price of money | ▼ tends to be pressured | Higher rates tend to pressure biotechnology, because expected profits sit further out and get discounted harder. |
Direction is a tendency across cycles, not a forecast. Sector mapping uses the Finnhub industry classification; geography uses country of registration, not revenue by region.
What actually moves Amgen
Rates show up in a large, mostly fixed stack with a floating slice. Debt carrying value was $54.60 billion at the end of 2025, much of it from the Horizon deal. The current portion was $4.60 billion. Swaps with a $6.7 billion notional convert part of the fixed notes to SOFR. That is the coupon that resets. The rest waits.
Trade is a pharma-specific tariff story with a pause attached. The filing says Amgen received relief from Section 232 tariffs for about three years, tied to US manufacturing investment, and warns that trade measures can still hurt. Plants in Puerto Rico, Ireland, the Netherlands and Singapore are part of that map. The United States took 73% of product sales, so foreign plants are a cost and tax question more than a demand question.
Conflict risk has a single-site version that a sector label skips. The filing's exposure runs through contract manufacturers, including the Israel site that makes all KRYSTEXXA drug substance. The less obvious policy channel is price setting at home: ENBREL was selected for Medicare prices from 2026, and Otezla for 2027. Three wholesalers, McKesson, Cencora and Cardinal, were 77% of worldwide gross revenues.
Drawn from the annual filing cited below. Not a forecast and not investment advice.
What Amgen sells and where it earns
Amgen makes and sells biologic and small molecule medicines for bone, heart, inflammation, cancer and rare diseases. Total revenue in 2025 was $36.75 billion, up 10%, and $35.15 billion of that was product sales. The United States took 73% of product sales and the rest of the world 27% (72% and 28% of total revenue). The portfolio is in transition. Prolia was still the largest product at $4.41 billion, but its U.S. patents on the underlying antibody expired in February 2025 and the company expects accelerated erosion as more biosimilars launch against Prolia and XGEVA. Growth came from Repatha, up 36% to $3.02 billion, EVENITY, up 34%, and TEZSPIRE, up 52%. ENBREL fell 33% to $2.23 billion as net selling price dropped 36% on 340B mix, the Medicare Part D redesign and commercial discounts. The 2023 Horizon deal brought TEPEZZA and KRYSTEXXA, which together sold $3.24 billion. MariTide, an obesity drug, began two global Phase 3 studies in March 2025. Amgen is also contesting IRS claims over profit allocation to its Puerto Rico operations that seek about $8.7 billion of additional tax, $3.1 billion of related repatriation tax, $2.0 billion of penalties, plus interest.
Customer concentration
Sales to three wholesalers, McKesson, Cencora and Cardinal Health, "each individually accounted for more than 10% of total revenues" in 2025, 2024 and 2023. Combined, they accounted for 77% of worldwide gross revenues in 2025.
Debt
The carrying value of debt was $54.60 billion at December 31, 2025, down from $60.10 billion a year earlier. Much of it dates from the $24 billion of notes issued in 2023 to buy Horizon. The current portion was $4.60 billion. The notes carry fixed coupons, and interest rate swaps with a notional amount of $6.7 billion convert part of that to floating, SOFR-based rates.
Risk factors that moved this year
- Most-Favored-Nation pricing is new. The May 2025 executive order and a July 31, 2025 letter asked drugmakers to give MFN prices to Medicaid and on new launches. In December 2025 Amgen said it is taking actions that satisfy the letter, including selling through its AmgenNow direct-to-patient program. The prior 10-K did not mention MFN.
- Tariffs are new and specific to pharma. The filing says Amgen received relief from Section 232 tariffs for about three years, pending a final determination, in recognition of its U.S. manufacturing investment, but warns that trade measures may still hurt results.
- IRA price setting is now in the numbers. CMS selected ENBREL for Medicare price setting from 2026 and selected Otezla in January 2025 for 2027, earlier than expected, which triggered an impairment of the Otezla intangible asset in 2025.
How this changes the exposure read
Amgen sits in Healthcare, where the generic template underrates policy and overrates oil. Trade/tariff is a real channel through pharmaceutical Section 232 tariffs, though Amgen has temporary relief, and its plants in Puerto Rico, Ireland, the Netherlands and Singapore matter for that. Conflict risk reaches it through single-source contract manufacturers, including the Israel site that makes all KRYSTEXXA drug substance. Oil shocks barely register. Chip/export rules are minor. Rates/Fed matter through $54.60 billion of debt, $6.7 billion of it swapped to floating. Credit stress mostly shows up in the three wholesalers that handle 77% of gross revenue.
Source: Amgen 10-K, FY2025. Checked 2026-10-07. Figures are from the filing and may differ from the live stats above.
What is moving it now
Key stats
Recent filings
Related tickers
- What a central bank rate decision means for your holdings
- When a rate move reaches the cash
- Conflict headlines that cut both ways
- Shipping chokepoints and what they do to equities
- Sanctions and export controls are not tariffs
- Methodology and editorial policy
Quotes may be delayed. Information only, not investment advice.